What is the recommended linezolid dose (mg/kg), dosing interval, maximum dose, treatment duration, and monitoring for pediatric patients?

Linezolid Dosing in Pediatrics

For pediatric patients, linezolid should be dosed at 10 mg/kg every 8 hours (IV or PO) for children birth through 11 years, and 600 mg every 12 hours for adolescents ≥12 years, with a maximum single dose of 600 mg. 1

Age-Based Dosing Algorithm

Neonates (Birth to <7 days)

• Gestational age <34 weeks:

  • Postnatal age ≤7 days: 10 mg/kg every 12 hours
  • Postnatal age >7 days: 10 mg/kg every 8 hours 2

• Gestational age ≥34 weeks:

  • 10 mg/kg every 8 hours 2

Critical caveat: Preterm neonates <7 days old (gestational age <34 weeks) have significantly lower systemic clearance and larger AUC values, requiring the every 12-hour interval initially. All neonates should transition to every 8-hour dosing by 7 days of life. 1

Infants and Children (>7 days to 11 years)

• 10 mg/kg IV or PO every 8 hours
• Maximum single dose: 600 mg 3, 1

This dosing achieves similar daily AUC values as the adult every 12-hour regimen because pediatric patients have more rapid clearance than adults. 1

Adolescents (≥12 years)

• 600 mg IV or PO every 12 hours 3, 1

By adolescence, clearance values approach adult levels, justifying the transition to twice-daily dosing. 1

Route of Administration

Linezolid has 100% oral bioavailability—IV and PO dosing are interchangeable without dose adjustment. 1 Switch from IV to PO when clinically appropriate based on patient tolerance and clinical response.

Treatment Duration by Indication

The duration varies by infection type:

• Uncomplicated skin/soft tissue infections: 10-14 days 1
• Complicated skin/soft tissue infections: 10-14 days 3, 1
• Community-acquired pneumonia: 10-14 days 1
• Nosocomial pneumonia: 10-14 days 1
• Vancomycin-resistant Enterococcus infections: 14-28 days 1
• Bacteremia/endocarditis: 14-28 days 3
• Bone/joint infections: Variable, typically 4-6 weeks 3
• CNS infections: Variable, typically ≥14 days 3

Monitoring Requirements

Hematologic Monitoring

Monitor complete blood count (CBC) weekly, especially with treatment >14 days. 4

• Thrombocytopenia risk increases significantly:

  • With trough concentrations >7 mg/L (particularly in cancer patients) 4
  • With treatment duration >14 days 4
  • In patients receiving concurrent chemotherapy (7-fold increased risk) 4

• Neutropenia and anemia risks increase:

  • With treatment >28 days 4
  • In chemotherapy-exposed patients 4

Therapeutic Drug Monitoring (TDM)

While not routinely required, consider TDM in:

• Critically ill patients
• Patients with suboptimal clinical response
• Infections with pathogens having MIC ≥2 μg/mL
• Prolonged therapy (>14 days)
• Cancer patients receiving chemotherapy 4, 5

Target concentrations:

• Trough (Cmin): 2-7 mg/L (avoid >7 mg/L to minimize thrombocytopenia risk) 6, 4
• Peak (Cmax): <15 mg/L (higher peaks with twice-daily dosing increase anemia risk) 4
• AUC24/MIC ratio: ≥100 for optimal efficacy 6

Special Populations

Critically Ill Children

Standard dosing (10 mg/kg every 8 hours) may be inadequate for pathogens with MIC ≥2 μg/mL. Consider:

• 15 mg/kg every 6 hours for MIC = 2 μg/mL (increases PTA from 63.6% to 94.6%) 5
• Adjust for elevated AST (>40 U/L), which significantly increases AUC 5

Cancer Patients

Exercise extreme caution—these patients have 20-fold increased leukopenia risk and 7-fold increased thrombocytopenia risk. 4

• Monitor CBC twice weekly
• Maintain trough <7 mg/L
• Consider dose reduction or alternative therapy if baseline platelets <100,000/μL

Renal Insufficiency

No dose adjustment required for linezolid itself (parent drug clearance unchanged), but metabolites accumulate. 1 The clinical significance is unknown, but use cautiously in severe renal impairment.

For hemodialysis patients: Administer after dialysis (30% removed in 3-hour session). 1

Common Pitfalls

1. Underdosing in young children: The every 8-hour interval is essential—every 12-hour dosing results in subtherapeutic exposure in children <12 years. 1

2. Prolonged therapy without monitoring: Hematologic toxicity risk escalates dramatically after 14 days, particularly thrombocytopenia. 4

3. Ignoring twice-daily vs. thrice-daily differences: At equivalent daily doses, twice-daily dosing produces higher peaks (19.65 vs. 13.67 mg/L) and increased anemia risk. 4 The every 8-hour regimen is preferred for safety.

4. Inadequate dosing for high-MIC pathogens: Standard 30 mg/kg/day may be insufficient for MIC = 2 μg/mL; consider 35-45 mg/kg/day in divided doses. 6

5. Overlooking drug interactions: Linezolid is a weak MAO inhibitor—avoid concurrent serotonergic agents and tyramine-rich foods.

Safety Profile

Linezolid is generally well-tolerated in pediatric patients. 7, 8 Most common adverse effects:

• Diarrhea (7.8-10.8%)
• Vomiting (9.4%)
• Headache (6.5%)
• Fever (14.1% in hospitalized patients)

Drug-related adverse effects occur at similar or lower rates compared to comparators (vancomycin, cefadroxil). 7